What is the half-life of VIP?

VIP has a half-life of ~1-2 minutes (plasma); tissue effects persist longer, which is why it's typically administered 1-4x daily (intranasal) or 1x daily (subcutaneous) for optimal therapeutic effect.

How do I reconstitute VIP?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Phase 3

VIP

Also known as: VIP Peptide, Vasoactive Intestinal Polypeptide, Aviptadil

Overview

Key Facts

Primary Goal: A 28-amino acid neuropeptide naturally produced in the gut, pancreas, brain, and immune cells

A 28-amino acid neuropeptide naturally produced in the gut, pancreas, brain, and immune cells. VIP is a potent anti-inflammatory and immune regulator that has gained significant popularity for treating chronic inflammatory conditions, mold illness (CIRS), long COVID, and neuroinflammation. It acts through VPAC1 and VPAC2 receptors to modulate immune tolerance and protect mucosal barriers. Half-Life ~1-2 minutes (plasma); tissue effects persist longer Typical Dose 50–200 mcg Frequency 1-4x daily (intranasal) or 1x daily (subcutaneous) Cycle Length 4-12 weeks, often longer under medical supervision

Dosing Information

Half-Life

~1-2 minutes (plasma); tissue effects persist longer

Typical Dose

50–200 mcg

Frequency

1-4x daily (intranasal) or 1x daily (subcutaneous)

Cycle Length

4-12 weeks, often longer under medical supervision

Administration Routes:

subcutaneousintravenous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Note: Protect from light. Do not freeze reconstituted solution.

Research Summary

Phase 3

VIP has been studied extensively since its discovery in 1970. Dr. Ritchie Shoemaker popularized its use in CIRS (mold illness) treatment protocols, where intranasal VIP demonstrated improvements in pulmonary artery pressure, quality of life, and inflammatory markers. The pharmaceutical form, aviptadil, entered Phase 2/3 trials for ARDS during COVID-19, showing improvements in respiratory function. Over 8,000 PubMed publications document VIP's anti-inflammatory, neuroprotective, and immunomodulatory properties. It is now one of the most commonly prescribed peptides in integrative and functional medicine.